| TB isolate¶ | TB relapse isolate+ | |||
| MGIT 960 phenotype | Resistance genotype | MGIT 960 phenotype | Resistance genotype | |
| Isoniazid mg·L−1 | katG Ser315Thr inhA wild type | katG Ser315Thr inhA wild type | ||
| 0.1 | Resistant | Resistant | ||
| 1.0 | Resistant | Resistant | ||
| 3.0 | Resistant | Resistant | ||
| 10.0 | Resistant | Resistant | ||
| Rifampicin mg·L−1 | rpoB Ser531Leu | rpoB Ser531Leu | ||
| 1.0 | Resistant | Resistant | ||
| 4.0 | Resistant | Resistant | ||
| 20.0 | Resistant | Resistant | ||
| Rifabutin mg·L−1 | ||||
| 0.1 | Resistant | Resistant | ||
| 0.4 | Resistant | Resistant | ||
| 2.0 | Not performed | Resistant | ||
| Ethambutol mg·L−1 | Not applicable | Not applicable | ||
| 5.0 | Susceptible | Susceptible | ||
| 12.5 | Susceptible | Susceptible | ||
| 50.0 | Susceptible | Susceptible | ||
| Streptomycin mg·L−1 | rpsL Lys88Arg rrs wild type (530 region) | rpsL Lys88Arg rrs wild type (530 region) | ||
| 1.0 | Resistant | Resistant | ||
| 4.0 | Susceptible | Susceptible | ||
| 20.0 | Susceptible | Susceptible | ||
| Amikacin mg·L−1 | rrs wild type (1400 region) | rrs wild type (1400 region) | ||
| 1.0 | Susceptible | Susceptible | ||
| 4.0 | Susceptible | Susceptible | ||
| 20.0 | Susceptible | Susceptible | ||
| Capreomycin mg·L−1 | rrs wild type (1400 region) tlyA wild type | rrs wild type (1400 region) tlyA wild type | ||
| 2.5 | Susceptible | Susceptible | ||
| 5.0 | Susceptible | Susceptible | ||
| 25.0 | Susceptible | Susceptible | ||
| Ethionamide mg·L−1 | ethA Ser266Arg inhA wild type | ethA Ser266Arg | ||
| 5.0 | Resistant | Resistant | ||
| 10.0 | Resistant | Resistant | ||
| 25.0 | Resistant | Resistant | ||
| Linezolid mg·L−1 | rrl A2572C rrl G2576T | rrl A2572C rrl G2576T | ||
| 1.0 | Resistant | Resistant | ||
| 4.0 | Resistant | Resistant | ||
| 16.0 | Susceptible | Susceptible | ||
| Moxifloxacin mg·L−1 | gyrA Asp94Tyr | gyrA Asp94Tyr | ||
| 0.25 | Resistant | Resistant | ||
| 0.5 | Resistant | Resistant | ||
| 2.5 | Susceptible | Resistant | ||
| 7.5 | Not performed | Susceptible | ||
| Para-aminosalicylic acid mg·L−1 | Not applicable | Not applicable | ||
| 4 | Susceptible | Susceptible | ||
| 16 | Susceptible | Susceptible | ||
| 64 | Susceptible | Susceptible | ||
| Cycloserine mg·L−1 | Not applicable | Not applicable | ||
| 50 | Susceptible | Susceptible | ||
| Pyrazinamide mg·L−1 | pncA Gly107 Stop | pncA Gly107Stop | ||
| 100 | Resistant | Resistant | ||
| Clofazimine mg·L−1 | Rv0678 wild type | Rv0678 fMet1Ala | ||
| 0.5 | Resistant | Resistant | ||
| 1.0 | Susceptible | Resistant | ||
| 4.0 | Susceptible | Resistant | ||
| Bedaquiline | atpE wild type Rv0678 wild type | atpE wild type Rv0678 fMet1Ala | ||
| Not available | Not available | Not applicable | ||
Critical concentrations of first- and second-line antituberculosis drugs in the MGIT 960 system are highlighted in bold. Critical concentrations are not established for para-aminosalicylic acid, cycloserine, clofazimine or bedaquiline in the BACTEC MGIT 960 system. TB: tuberculosis. #: using the BACTEC MGIT 960 system (Becton-Dickinson Inc., East Rutherford, NJ, USA) with the TB eXiST module (Becton-Dickinson Microbiology Systems, Sparks, MD, USA); ¶: January 2011; +: August 2013.